MA30808B1 - Compositions et procedes permettant de diagnostiquer et de traiter le cancer - Google Patents

Compositions et procedes permettant de diagnostiquer et de traiter le cancer

Info

Publication number
MA30808B1
MA30808B1 MA31810A MA31810A MA30808B1 MA 30808 B1 MA30808 B1 MA 30808B1 MA 31810 A MA31810 A MA 31810A MA 31810 A MA31810 A MA 31810A MA 30808 B1 MA30808 B1 MA 30808B1
Authority
MA
Morocco
Prior art keywords
treating cancer
diagnosing
compositions
methods
relates
Prior art date
Application number
MA31810A
Other languages
English (en)
Inventor
Austin Gurney
Timothy Hoey
Sanjeev Satyal
Fumiko Axelrod
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MA30808B1 publication Critical patent/MA30808B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'INVENTION CONCERNE UN ANTICORPS ISOLÉ QUI SE FIXE DE MANIÈRE SPÉCIFIQUE À UN DOMAINE EXTRACELLULAIRE DE DLL4 HUMAIN ET AFFECTE LA CROISSANCE D'UNE TUMEUR COMPRENANT DES CELLULES SOUCHES CANCÉREUSES. L'INVENTION CONCERNE ÉGALEMENT UN PROCÉDÉ POUR TRAITER LE CANCER COMPRENANT L'ADMINISTRATION D'UNE QUANTITÉ EFFICACE DE MANIÈRE THÉRAPEUTIQUE D'UN ANTICORPS ANTI-DLL4.
MA31810A 2006-09-29 2009-04-22 Compositions et procedes permettant de diagnostiquer et de traiter le cancer MA30808B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84790406P 2006-09-29 2006-09-29
US88626007P 2007-01-23 2007-01-23
US94254207P 2007-06-07 2007-06-07

Publications (1)

Publication Number Publication Date
MA30808B1 true MA30808B1 (fr) 2009-10-01

Family

ID=39268983

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31810A MA30808B1 (fr) 2006-09-29 2009-04-22 Compositions et procedes permettant de diagnostiquer et de traiter le cancer

Country Status (27)

Country Link
US (5) US7750124B2 (fr)
EP (3) EP2562188A3 (fr)
JP (3) JP5535633B2 (fr)
KR (1) KR101477824B1 (fr)
AU (1) AU2007305443B2 (fr)
BR (1) BRPI0717431A2 (fr)
CA (1) CA2664738C (fr)
CO (1) CO6180466A2 (fr)
CR (1) CR10667A (fr)
CY (1) CY1117154T1 (fr)
DK (1) DK2066694T3 (fr)
EA (1) EA018260B1 (fr)
ES (1) ES2557953T3 (fr)
HR (1) HRP20160082T1 (fr)
HU (1) HUE028379T2 (fr)
IL (1) IL197721A (fr)
MA (1) MA30808B1 (fr)
ME (1) ME02371B (fr)
MX (1) MX2009003229A (fr)
NO (1) NO20091635L (fr)
NZ (1) NZ576404A (fr)
PL (1) PL2066694T3 (fr)
PT (1) PT2066694E (fr)
RS (1) RS54452B1 (fr)
SI (1) SI2066694T1 (fr)
WO (1) WO2008042236A2 (fr)
ZA (1) ZA200901615B (fr)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
HRP20160082T1 (hr) 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008091641A2 (fr) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions et procédés utilisés pour le diagnostic et le traitement du cancer
EP2125013A4 (fr) * 2007-01-26 2010-04-07 Bioinvent Int Ab Inhibiteurs de la signalisation dll4 et utilisations associees
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
ES2694018T3 (es) 2007-07-02 2018-12-17 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el tratamiento y el diagnóstico del cáncer
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
EP2282769A4 (fr) 2008-04-29 2012-04-25 Abbott Lab Immunoglobulines à double domaine variable et utilisations
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
EP2297209A4 (fr) 2008-06-03 2012-08-01 Abbott Lab Immunoglobulines à deux domaines variables et leurs utilisations
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2010019702A2 (fr) 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Agents de liaison à ddr1 et leurs méthodes d'utilisation
CN102264763B (zh) * 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
US9067986B2 (en) * 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
CA2771575A1 (fr) * 2009-08-29 2011-03-03 Abbott Laboratories Proteines therapeutiques se liant a dll4
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3485908B1 (fr) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Combinaison thérapeutique et utilisation d'anticorps antagonistes de dll4 et d'agents anti-hypertenseurs
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
US20110165162A1 (en) * 2009-12-01 2011-07-07 Oncomed Pharmaceuticals, Inc. Methods for Treating Cancers Comprising K-ras Mutations
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
WO2011109298A2 (fr) * 2010-03-02 2011-09-09 Abbott Laboratories Protéines thérapeutiques de liaison à dll4
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012024543A1 (fr) * 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings Biomarqueurs circulants pour une maladie
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US20130323265A1 (en) * 2010-11-15 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
WO2012092539A2 (fr) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Anticorps contre dll4 et leurs utilisations
CN103562723B (zh) * 2011-03-27 2017-04-26 欧恩克斯特姆诊断学（毛里求斯）私人有限公司 用于识别肿瘤细胞的标记、方法及其试剂盒
EP2721070A1 (fr) * 2011-06-17 2014-04-23 Harris, Adrian, L. Méthodes permettant d'amplifier la réponse aux radiations dans un traitement tumoral à base d'anticorps anti-dll4
WO2013012747A1 (fr) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Agents de fixation aux protéines rspo et leurs utilisations
US20130108641A1 (en) * 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
JP2015520172A (ja) * 2012-05-31 2015-07-16 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｄｌｌ−４に結合する抗原結合蛋白質
MX2014014951A (es) 2012-06-06 2015-03-13 Oncomed Pharm Inc Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
CN104854132A (zh) 2012-07-13 2015-08-19 昂考梅德药品有限公司 Rspo3结合剂及其用途
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
WO2014062659A2 (fr) * 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Méthodes de traitement de maladies oculaires
CA2889638A1 (fr) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methodes et surveillance d'un traitement par un antagoniste de dll4
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
WO2014089169A2 (fr) 2012-12-04 2014-06-12 Oncomed Pharmaceuticals, Inc. Immunothérapie par des agents de liaison
JP6449537B2 (ja) * 2012-12-27 2019-01-09 日本メジフィジックス株式会社 抗腫瘍剤、及び、抗腫瘍用キット
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
GB201312727D0 (en) * 2013-07-16 2013-08-28 Isis Innovation Modulators
MX374785B (es) 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
EP3077546A4 (fr) 2013-12-02 2017-04-26 Oncomed Pharmaceuticals, Inc. Identification de biomarqueurs predictifs associes a des inhibiteurs de la voie wnt
US10214584B2 (en) 2014-01-15 2019-02-26 Order-Made Medical Research Inc. Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody
KR102493543B1 (ko) * 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
WO2016044295A1 (fr) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Traitement de maladies fibrotiques
EP3212233B1 (fr) * 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Thérapie combinée pour le traitement d'une maladie
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
SG10201913538VA (en) 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP7035026B2 (ja) 2016-05-19 2022-03-14 サンタ アナ テック エルエルシー 加熱された切除ゾーンを生成し組織に適用するためのダブルバルーン構造を有するカテーテル
US11026996B2 (en) * 2016-05-25 2021-06-08 The Trustees Of Columbia University In The City Of New York Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
CA3034093A1 (fr) 2016-08-23 2018-03-01 The Regents Of The University Of California Polypeptides chimeriques clivables de maniere proteolytique et leurs procedes d'utilisation
EP3515491A4 (fr) 2016-09-21 2020-09-16 Aptevo Research and Development LLC Protéines de liaison à cd123 et compositions et procédés associés
EP3538548A4 (fr) 2016-11-08 2020-08-19 Delinia, Inc. Variants d'il-2 pour le traitement de maladies auto-immunes
MX2019006072A (es) 2016-11-30 2019-08-14 Oncomed Pharm Inc Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
DK3624837T3 (da) 2017-05-16 2025-09-29 Five Prime Therapeutics Inc Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling
CA3102080A1 (fr) 2018-06-01 2019-12-05 Santa Anna Tech Llc Procedes de traitement d'ablation a base de vapeur a plusieurs etapes et systemes de generation et de distribution de vapeur
WO2020056031A1 (fr) 2018-09-11 2020-03-19 Aqua Heart, Inc. Systèmes d'ablation à vapeur chauffée et procédés de traitement d'états cardiaques
AU2019380595A1 (en) 2018-11-15 2021-06-03 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with VEGF/DLL4 binding agent
EP4021326A4 (fr) 2019-08-28 2023-09-13 Santa Anna Tech LLC Systèmes et procédés d'ablation de tissu de la prostate
EP4090276A4 (fr) 2020-01-15 2024-05-08 Aqua Medical, Inc. Système d'ablation à la vapeur avec contrôle simplifié de l'apport de vapeur
WO2022077020A1 (fr) 2020-10-08 2022-04-14 Santa Anna Tech Llc Cathéters d'ablation à visualisation, systèmes associés et méthodes associées
WO2023149977A1 (fr) * 2022-02-04 2023-08-10 Mereo Biopharma 5, Inc. Méthodes de traitement du cancer

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2248608B1 (fr) * 1973-10-17 1977-05-27 Labo Electronique Physique
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DK0861261T3 (da) * 1995-06-28 2009-12-14 Imp Cancer Res Tech Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
JPH09124697A (ja) * 1995-11-01 1997-05-13 Toagosei Co Ltd ペプチド及びモノクローナル抗体
EP0861894B1 (fr) 1995-11-17 2006-03-08 Asahi Kasei Kabushiki Kaisha Polypeptide suppresseur et de differenciation
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6952498A (en) 1997-04-04 1998-10-30 Millenium Pharmaceuticals, Inc. Novel human delta3 compositions and therapeutic and diagnostic uses therefor
US20030180784A1 (en) * 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
US20060122373A1 (en) * 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
DE69829891T2 (de) * 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
CA2288343A1 (fr) 1997-04-25 1998-11-05 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP0979281B1 (fr) * 1997-05-02 2005-07-20 Genentech, Inc. Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP4171528B2 (ja) 1997-05-14 2008-10-22 旭化成株式会社 新規な分化抑制剤
AU8162898A (en) 1997-06-18 1999-01-04 Trustees Of Columbia University In The City Of New York, The Angiogenic modulation by notch signal transduction
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
CA2337492A1 (fr) 1998-07-27 2000-02-10 Amgen Inc. Polypeptides relatifs a delta
EP1179541B1 (fr) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions et procédes de traitment du cancer par l'inhibition sélective du VEGF
CN101433715B (zh) 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
CA2378403A1 (fr) 1999-07-26 2001-02-01 Genentech, Inc. Nouveaux polynucleotides et technique d'utilisation de ceux-ci
CA2391455A1 (fr) 1999-12-01 2001-06-07 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
JP2003530124A (ja) 2000-04-05 2003-10-14 麒麟麦酒株式会社 新規幹細胞成長因子様ポリペプチドおよびポリヌクレオチドに関する方法および物質
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
GB0014185D0 (en) * 2000-06-09 2000-08-02 Novartis Res Found Compound and method
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US20050089518A1 (en) * 2001-12-07 2005-04-28 Clarke Michael F. Prospective identification and characterization of breast cancer stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
EP1410018A1 (fr) * 2001-07-25 2004-04-21 Lorantis Limited Procede de detection de modulateurs de signalisation de notch
AU2002317333C1 (en) * 2001-08-01 2009-06-25 University Of Bristol VEGF isoform
US20050137130A1 (en) * 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
EP1446424A2 (fr) * 2001-11-14 2004-08-18 Lorantis Limited Composition comprenant des inhibiteurs de la voie signalation de notch pour la modulation du systeme immunitaire
JP2005526701A (ja) * 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
GB0218879D0 (en) * 2002-08-14 2002-09-25 Lorantis Ltd Medical treatment
EP1537145A1 (fr) * 2002-09-10 2005-06-08 Lorantis Limited Composition pharmaceutique et traitements medicaux comprenant des proteines a ligand notch
CA2519875C (fr) 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Methode favorisant la regression de tumeurs au moyen d'inhibiteurs du vegf (facteur de croissance de l'endothelium vasculaire)
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
CA2534898A1 (fr) * 2003-08-08 2005-02-17 Immunomedics, Inc. Anticorps bispecifiques pour induire l'apoptose de cellules tumorales et malades
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
EP2583685A1 (fr) 2004-06-10 2013-04-24 Regeneron Pharmaceuticals, Inc. Procédé d'administration et d'utilisation d'inhibiteurs de VEGF pour le traitement d'un cancer humain
EP1755645A2 (fr) 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Methode d'administration d'inhibiteurs de vegf pour le traitement d'un epanchement pleural malin
WO2006028936A2 (fr) 2004-09-02 2006-03-16 Genentech, Inc. Molecules heteromultimeriques
US20080254031A1 (en) 2004-09-09 2008-10-16 Exonhit Therapeutics Sa Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトＩｇＧ４抗体
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US8048418B2 (en) * 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
JP2008519829A (ja) 2004-11-10 2008-06-12 ヒュブレヒト ラボラトリウム Ｎｏｔｃｈ経路活性化の阻害による腸腺腫および／または腺癌の処置
EP1812064A4 (fr) * 2004-11-19 2009-07-08 Cornell Res Foundation Inc Utilisation des cellules du recepteur du facteur de croissance endothelial vasculaire dans le traitement et la surveillance du cancer et dans le criblage d'agents chimiotherapeutiques
US7432107B2 (en) 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
EP1853298A2 (fr) 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Melange therapeutique d'un antagoniste du vegf (vegf trap) et d'un agent anti-hypertension
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
JP5838021B2 (ja) * 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
RU2007146986A (ru) * 2005-06-02 2009-06-27 ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи (US) Способы лечения опухолей головного мозга с использованием антител
AU2006279658A1 (en) 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a VEGF antagonist
EP1928486A2 (fr) * 2005-09-01 2008-06-11 Vasgene Therapeutics, Inc. Methodes d'utilisation et d'identification de modulateurs de delta-like 4
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
PL1962895T3 (pl) * 2005-12-16 2013-06-28 Regeneron Pharma Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
CA2642685A1 (fr) 2006-02-17 2007-08-30 Gilead Colorado, Inc. Traitement antihypertenseur
US7354582B2 (en) * 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
JP2009539870A (ja) * 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
AU2007319672B2 (en) 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
US7919092B2 (en) * 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
WO2007147901A1 (fr) 2006-06-22 2007-12-27 Novo Nordisk A/S Production d'anticorps bispécifiques
NZ574794A (en) 2006-08-07 2011-06-30 Regeneron Pharma Use of delta-like ligand 4 (DLL4) antagonists for treating eye vascular and ischemic injury
EP2471816A1 (fr) * 2006-08-30 2012-07-04 Genentech, Inc. Anticorps multi-spécifiques
HRP20160082T1 (hr) * 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
CA2666974A1 (fr) * 2006-10-20 2008-11-06 Schering Corporation Anticorps anti-vegf entierement humains et leurs procedes d'utilisation
US20100166746A1 (en) 2006-12-04 2010-07-01 Medlmmune Way High potency recombinant antibodies, methods for producing them and use in cancer therapy
JP2010512407A (ja) * 2006-12-11 2010-04-22 ジェネンテック インコーポレイテッド 新生物を処置するための組成物および方法
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
US20080248033A1 (en) * 2006-12-19 2008-10-09 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
EP2120996A2 (fr) 2006-12-20 2009-11-25 Vasgene Therapeutics, Inc. Procédés d'utilisation et d'identification de modulateurs de dll4
EP2125013A4 (fr) * 2007-01-26 2010-04-07 Bioinvent Int Ab Inhibiteurs de la signalisation dll4 et utilisations associees
WO2008137318A1 (fr) 2007-05-04 2008-11-13 Ironwood Pharmaceuticals, Inc. Compositions et procédés de traitement de troubles associés à la rétention de sel ou de fluide
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
RU2010120674A (ru) * 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
AU2008315414A1 (en) * 2007-10-25 2009-04-30 Philogene, Inc. Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (VEGF)
WO2009075565A1 (fr) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Méthodes de régulation de la vasculogenèse
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
EP2282769A4 (fr) * 2008-04-29 2012-04-25 Abbott Lab Immunoglobulines à double domaine variable et utilisations
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
UY32317A (es) * 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
AR076344A1 (es) * 2009-04-20 2011-06-01 Genentech Inc Metodo de terapia complementaria contra el cancer
WO2010124009A2 (fr) 2009-04-21 2010-10-28 Schering Corporation Anticorps anti-vegf entièrement humains et méthodes d'utilisation de ceux-ci
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CA2766166A1 (fr) * 2009-07-08 2011-01-13 Amgen Inc. Conception de molecules fc d'anticorps exemptes d'agregation et stable par ingenierie de l'interface du domaine ch3
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
EP3485908B1 (fr) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Combinaison thérapeutique et utilisation d'anticorps antagonistes de dll4 et d'agents anti-hypertenseurs
JP2013508308A (ja) 2009-10-23 2013-03-07 ガーバン インスティテュート オブ メディカル リサーチ 修飾可変ドメイン分子、ならびにその産生および使用方法
US20110165162A1 (en) * 2009-12-01 2011-07-07 Oncomed Pharmaceuticals, Inc. Methods for Treating Cancers Comprising K-ras Mutations
KR20120117931A (ko) 2010-02-12 2012-10-24 온코메드 파마슈티칼스, 인크. 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법
WO2011109298A2 (fr) 2010-03-02 2011-09-09 Abbott Laboratories Protéines thérapeutiques de liaison à dll4
US20130323265A1 (en) 2010-11-15 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
WO2013012747A1 (fr) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Agents de fixation aux protéines rspo et leurs utilisations
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
CN104854132A (zh) 2012-07-13 2015-08-19 昂考梅德药品有限公司 Rspo3结合剂及其用途
CA2889638A1 (fr) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methodes et surveillance d'un traitement par un antagoniste de dll4

Also Published As

Publication number Publication date
HUE028379T2 (en) 2016-12-28
US20080187532A1 (en) 2008-08-07
PL2066694T3 (pl) 2016-04-29
ES2557953T3 (es) 2016-01-29
ME02371B (fr) 2016-06-20
EP2562188A3 (fr) 2013-03-06
US20160367667A1 (en) 2016-12-22
CO6180466A2 (es) 2010-07-19
US9228020B2 (en) 2016-01-05
WO2008042236A3 (fr) 2008-07-31
CA2664738C (fr) 2017-03-07
NZ576404A (en) 2012-02-24
ZA200901615B (en) 2009-12-30
IL197721A (en) 2015-03-31
HK1133268A1 (en) 2010-03-19
KR20090078334A (ko) 2009-07-17
PT2066694E (pt) 2016-01-27
EP2066694B1 (fr) 2015-11-04
EP2066694A2 (fr) 2009-06-10
HRP20160082T1 (hr) 2016-02-26
NO20091635L (no) 2009-06-26
JP2014158469A (ja) 2014-09-04
US20140147443A9 (en) 2014-05-29
US20130266569A1 (en) 2013-10-10
IL197721A0 (en) 2011-08-01
KR101477824B1 (ko) 2015-01-02
EP2562188A2 (fr) 2013-02-27
EA018260B1 (ru) 2013-06-28
US20100316637A1 (en) 2010-12-16
JP2010504755A (ja) 2010-02-18
JP2017002076A (ja) 2017-01-05
JP5535633B2 (ja) 2014-07-02
EP3357932A1 (fr) 2018-08-08
SI2066694T1 (sl) 2016-02-29
EP2066694A4 (fr) 2010-05-05
JP5997194B2 (ja) 2016-09-28
MX2009003229A (es) 2009-06-18
BRPI0717431A2 (pt) 2013-11-12
US20190060453A1 (en) 2019-02-28
DK2066694T3 (en) 2016-02-08
RS54452B1 (sr) 2016-06-30
CY1117154T1 (el) 2017-04-05
US9376497B2 (en) 2016-06-28
AU2007305443B2 (en) 2012-08-23
US7750124B2 (en) 2010-07-06
WO2008042236A2 (fr) 2008-04-10
CA2664738A1 (fr) 2008-04-10
AU2007305443A1 (en) 2008-04-10
EA200970335A1 (ru) 2009-10-30
CR10667A (es) 2009-05-25

Similar Documents

Publication Publication Date Title
MX2009003229A (es) Composiciones y metodos para diagnosticar y tratar cancer.
MA32448B1 (fr) Agents de liaison de recepteur notch1 et procedes d'utilisation
WO2007145840A3 (fr) Compositions et procédés de diagnostic et de traitement du cancer
ES2788151T3 (es) Kits y ensayos de diagnóstico para la detección del receptor 1 de folato
EA201170136A1 (ru) Мультимасштабный метод конечных объемов для моделирования резервуара
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
WO2007053577A3 (fr) Compositions et procedes pour diagnostiquer et traiter un cancer
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
NO20066075L (no) Antistofflegemiddelkonjugater og fremgangsmater
EA201690111A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
MA30158B1 (fr) Compositions et procedes d'utilisation d'anticorps contre dickkopf-1
EA200700321A1 (ru) Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
Zhang et al. Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding
MX2008013397A (es) Analisis de perfilamiento de expresion diferencial de fenotipos de cultivo celular y usos de los mismos.
Fiszman et al. Activation of muscarinic cholinergic receptors induces MCF-7 cells proliferation and angiogenesis by stimulating nitric oxide synthase activity
Yamaguchi et al. Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma
AU2003242815A1 (en) Method for the characterisation of circulating tumour cells stemming from solid cancers
Obaid et al. Immunofluorescence profiling of collagen subtypes is a predictor of treatment outcomes in pancreatic cancer
Adams et al. Human breast cancer cell lines and tissues express tartrate-resistant acid phosphatase (TRAP)
EA200701599A1 (ru) Способ и композиция для восстановления сердечной ткани
Gkizas et al. Aldosterone receptor blockade inhibits degenerative processes in the early stage of calcific aortic stenosis
JP6207531B2 (ja) 放射線感受性を調節するためのｈｅｒ３阻害剤
EA200701826A1 (ru) Способ и композиция для лечения диабета
MA30811B1 (fr) Compositions therapeutiques permettant d'augmenter l'effet d'une therapie aux anticorps contre le recepteur du facteur de croissance epidermique
MA33668B1 (fr) Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer